Polycythemia screening: Difference between revisions

	Polycythemia Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Polycythemia from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
Diagnostic Study of Choice
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
X-ray
Echocardiography or Ultrasound
CT scan
MRI
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Interventions
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Polycythemia screening On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Polycythemia screening All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Polycythemia screening
CDC on Polycythemia screening
Polycythemia screening in the news
Blogs on Polycythemia screening
Directions to Hospitals Treating Polycythemia
Risk calculators and risk factors for Polycythemia screening

← Older edit Newer edit →

VisualWikitext

Revision as of 20:44, 24 September 2020

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief:

Overview

There is insufficient evidence to recommend routine screening for [disease/malignancy].

OR

According to the [guideline name], screening for [disease name] is not recommended.

OR

According to the [guideline name], screening for [disease name] by [test 1] is recommended every [duration] among patients with [condition 1], [condition 2], and [condition 3].

Screening

There is insufficient evidence to recommend routine screening for [disease/malignancy].

OR

According to the [guideline name], screening for [disease name] is not recommended.

OR

According to the [guideline name], screening for [disease name] by [test 1] is recommended every [duration] among patients with:

[Condition 1]
[Condition 2]
[Condition 3]

References

Template:WS Template:WH

@@ Line 3: / Line 3: @@
 {{CMG}} {{AE}}
 ==Overview==
-If left untreated, [#]% of patients with [disease name] may progress to develop [manifestation 1], [manifestation 2], and [manifestation 3].
+There is insufficient evidence to recommend routine screening for [disease/malignancy].
 OR
-Common complications of [disease name] include [complication 1], [complication 2], and [complication 3].
+According to the [guideline name], screening for [disease name] is not recommended.
 OR
-Prognosis is generally excellent/good/poor, and the 1/5/10-year mortality/survival rate of patients with [disease name] is approximately [#]%.
+According to the [guideline name], screening for [disease name] by [test 1] is recommended every [duration] among patients with [condition 1], [condition 2], and [condition 3].
-==Natural History, Complications, and Prognosis==
+==Screening==
+There is insufficient evidence to recommend routine screening for [disease/malignancy].
-===Natural History===
+OR
-*The symptoms of (disease name) usually develop in the first/ second/ third decade of life, and start with symptoms such as ___.
-*The symptoms of (disease name) typically develop ___ years after exposure to ___.
+According to the [guideline name], screening for [disease name] is not recommended.
-*If left untreated, [#]% of patients with [disease name] may progress to develop [manifestation 1], [manifestation 2], and [manifestation 3].
+OR
-===Complications===
+According to the [guideline name], screening for [disease name] by [test 1] is recommended every [duration] among patients with:
-*Common complications of [disease name] include:
+*[Condition 1]
-**[Complication 1]
+*[Condition 2]
-**[Complication 2]
+*[Condition 3]
-**[Complication 3]
-===Prognosis===
-*Prognosis is generally excellent/good/poor, and the 1/5/10-year mortality/survival rate of patients with [disease name] is approximately [--]%.
-*Depending on the extent of the [tumor/disease progression] at the time of diagnosis, the prognosis may vary. However, the prognosis is generally regarded as poor/good/excellent.
-*The presence of [characteristic of disease] is associated with a particularly [good/poor] prognosis among patients with [disease/malignancy].
-*[Subtype of disease/malignancy] is associated with the most favorable prognosis.
-*The prognosis varies with the [characteristic] of tumor; [subtype of disease/malignancy] have the most favorable prognosis.
 ==References==

Polycythemia screening: Difference between revisions

Revision as of 20:44, 24 September 2020

Overview

Screening

References

Navigation menu

Search